Shorter Herceptin treatment after chemotherapy for early breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether giving Herceptin for a shorter time after chemotherapy works as well as the usual longer treatment for early-stage HER2-positive breast cancer. It aims to reduce side effects and treatment burden while keeping the same benefits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with early-stage breast cancer that has not spread to lymph nodes or other parts of the body.
- Your tumor is smaller than 30 mm (about 1.2 inches).
- Your cancer is HER2-positive, which means it has a specific protein that helps it grow.
- You are eligible to receive a type of chemotherapy called paclitaxel, given weekly.
- Your heart function is normal, with an ejection fraction above 50% (a measure of how well your heart pumps).
- You have not had previous treatment targeting HER2, except for Herceptin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if taking oral chemotherapy pills with trastuzumab (Herceptin) works as well as IV chemo (paclitaxel) with Herceptin after surgery for HER2-positive, lymph node-negative early breast cancer. It aims to find a more convenient treatment option.
This Phase 2 study tests two different medicines given after breast surgery to reduce the risk of cancer coming back. It is only for people with early-stage HER2-positive breast cancer with limited or no lymph node spread.
This trial tests whether a less intense treatment before surgery works as well as the standard approach for early-stage HER2-positive breast cancer. It aims to reduce side effects while still being effective.
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
This trial tests a new antibody-drug combination (trastuzumab rezetecan, also called T-DXd) for patients with HER2-positive breast cancer whose tumor did not fully disappear after initial chemotherapy. The goal is to see if this drug can reduce the risk of cancer coming back.
This trial tests a new drug called trastuzumab rezetecan given before surgery for early-stage HER2-positive breast cancer. It's designed for patients whose cancer doesn't respond well to standard HER2-targeted treatments.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.